Alexion recently announced it would lay off approximately 20 percent of its workforce and renew its focus on rare disease drugs. This round of layoffs follow a 7 percent reduction in its workforce that was already announced in March.
The company, which had nearly 3,100 employees at the end of 2016, also plans to close some offices and manufacturing sites, including one in Rhode Island.
Alexion will move from its New Haven, Connecticut headquarters to Boston by mid-2018.
The drugmaker expects the restructuring to save $270 million each year by 2019.
Read the Reuters report